Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Empagliflozin (Jardiance) for preventing cardiovascular death in patients with type 2 diabetes mellitus and high cardiovascular risk. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Type 2 diabetes is a disease that results in the levels of sugar in the blood being too high. This can cause damage to the eyes, nerves, kidneys and other tissues, and can greatly increase the chances of heart attacks and strokes, especially when combined with high blood pressure and high blood cholesterol levels.
Empagliflozin is a drug currently used to treat type 2 diabetes. It is given as a tablet that is taken once daily. In a large study of patients, empagliflozin reduced the risk of getting high blood pressure, heart attacks and strokes in people with type 2 diabetes.
If licensed in the UK, empagliflozin will offer type 2 diabetes patients who are at risk of developing heart disease and strokes, an additional treatment option which can be used with other diabetes drugs. Indexing Status Subject indexing assigned by CRD MeSH Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000818 Date abstract record published 22/06/2016 |